YieldMax HIMS Option Income Strategy ETF(HIYY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HIYY YieldMax HIMS Option Income Strategy ETF

交易中 03-10 15:10:17 EDT

15.87

+0.26

+1.67%

最高18.08	最低15.81	成交量5.33万
今开17.38	昨收15.61	日振幅14.53%
总市值277.73万	流通市值158.70万	总股本17.50万
成交额87.22万	换手率53.26%	流通股本10.00万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"HIYY","market":"US","secType":"STK","nameCN":"YieldMax HIMS Option Income Strategy ETF","latestPrice":15.87,"timestamp":1773169580062,"preClose":15.61,"halted":0,"volume":53262,"delay":0,"changeRate":0.016655989750160142,"floatShares":100000,"shares":175000,"eps":0,"marketStatus":"交易中","change":0.26,"latestTime":"03-10 15:10:17 EDT","open":17.38,"high":18.08,"low":15.8123,"amount":872176.754592,"amplitude":0.145272,"askPrice":15.98,"askSize":500,"bidPrice":15.86,"bidSize":500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1773172800000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":15.61,"sharesOutstanding":1150000,"nav":11.64,"aum":2037000,"dividendRate":0.593233,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":16.7,"preClose":15.61,"latestTime":"08:00 EDT","volume":10,"amount":164.74,"timestamp":1773144006279,"change":1.09,"changeRate":0.069827,"amplitude":0.099936},"postHourTrading":{"tag":"盘后","latestPrice":15.97,"preClose":15.61,"latestTime":"19:16 EDT","volume":1627,"amount":25512.12,"timestamp":1773098205260,"change":0.36,"changeRate":0.023062,"amplitude":0.023062},"volumeRatio":1.002691,"impliedVol":0.3193,"impliedVolPercentile":0.2818},"requestUrl":"/m/hq/s/HIYY","defaultTab":"news","newsList":[{"id":"1126668487","title":"花旗集团上调Hims & Hers Health Inc评级至中性，目标价大幅提升至24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1126668487","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126668487?lang=zh_cn&edition=full","pubTime":"2026-03-10 18:27","pubTimestamp":1773138443,"startTime":"0","endTime":"0","summary":"花旗集团最新发布的研究报告显示，已将对远程医疗公司Hims & Hers Health Inc的股票评级从\"卖出\"上调至\"中性\"。与此同时，该机构将其目标股价从13.25美元显著调高至24美元，涨幅超过80%。\n此次评级调整反映了花旗对该公司业务发展前景的重新评估。目标价的大幅提升可能基于对公司营收增长、市场份额扩大或盈利能力改善的积极预期。作为专注于男性与女性健康领域的远程医疗服务商，Hims & Hers Health Inc近期在扩大用户基础和优化服务模式方面取得进展，这或是引发机构重新评估其价值的关键因素。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HMYY","HIMZ","HIMY","BK4196","HIYY","HIMS"],"gpt_icon":0},{"id":"2618147987","title":"花旗上调Hims & Hers Health(HIMS.US)评级至“中性” 看好诺和诺德协议下的合规溢价","url":"https://stock-news.laohu8.com/highlight/detail?id=2618147987","media":"智通财经","labels":["executive","rating"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618147987?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:07","pubTimestamp":1773130046,"startTime":"0","endTime":"0","summary":"花旗银行在最新的研究报告中对这一合作给予了高度评价，并将其视为 Hims & Hers 发展史上的重要转折点。花旗分析师指出，通过引入官方正版药物，Hims & Hers 成功摆脱了长期困扰其业务模式的合规性阴影与法律风险。这一利好消息在二级市场引发了剧烈反弹，Hims & Hers 的股价在消息公布后的交易时段内一度飙升超过 35%，周一收涨40.79%，报22.16美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412108.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,rating","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","LU1244550494.USD","HIMS","LU2360032135.SGD","BK4207","LU1791807156.HKD","LU1162221912.USD","LU1267930227.SGD","LU2125154778.USD","IE00BSNM7G36.USD","LU1244550221.USD","IE00BKVL7J92.USD","BK4532","LU0098860793.USD","NVOX","LU1668664300.SGD","LU0980610538.SGD","BK4196","LU0106831901.USD","LU1366192091.USD","BK4585","LU0052756011.USD","LU0130517989.USD","LU0128525689.USD","BK4566","LU2462157665.USD","BK4534","LU0477156953.USD","IE00BZ1G4Q59.USD","BK4599","LU0314106906.USD","LU0170899867.USD","HMYY","LU1244550577.SGD","HIMY","LU0130102774.USD","NVOH","LU0310800965.SGD","LU0162691827.USD","LU1093756325.SGD","LU2125154935.USD","LU1093756168.USD","LU2417539215.USD","LU1201861249.SGD","LU2236285917.USD","LU0072461881.USD","LU1506573853.SGD","LU2456880835.USD","LU0320765646.SGD","BK4504","HIYY","LU0154236417.USD","LU0648001328.SGD","HIMZ","BK4559","BK4007"],"gpt_icon":1},{"id":"1177597123","title":"ETF日报｜2倍做多Hims & Hers ETF涨超81%；三倍做多半导体ETF涨超11%；成长风格领跑","url":"https://stock-news.laohu8.com/highlight/detail?id=1177597123","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177597123?lang=zh_cn&edition=full","pubTime":"2026-03-10 10:30","pubTimestamp":1773109800,"startTime":"0","endTime":"0","summary":"大宗商品中，白银相关ETF显著走强，原油做多品种回落。该产品两倍做多在线医疗平台公司$Hims & Hers Health$，因底层公司股价上涨，杠杆机制放大当日涨幅。$诺和诺德$计划在Hims & Hers Health平台销售减重药物，双方结束此前的法律纠纷，公司股价大幅上涨。该产品围绕Hims & Hers Health开展期权收益策略，因公司股价上行，份额净值同步走高。$2倍做多恐慌指数期货ETF$下跌19.40%。行业指数ETF涨幅Top 5$三倍做多半导体ETF-Direxion Daily$上涨11.34%。债券ETF涨幅Top 5$First Trust SSI Strategic Convertible Securities ETF$上涨2.02%。","market":"us","thumbnail":"https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6ff7c068e21399ce793d8151cce49f41","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","SLV","BE","TQQQ","CRCD","LU2264538146.SGD","AGQ","BK4541","LITX","CWB","SOXL","UVIX","VCLT","RDWU","EWY","LU2249611893.SGD","BK4182","SPLB","IBB","YINN","LU1064131342.USD","DGZ","HIMS","LU0444971666.USD","LU0823414478.USD","NLR","OIH","LU2543165471.USD","LU2294711713.HKD","LU0957808578.USD","LU2357125470.USD","EDC","ICVT","LU0823414551.USD","BEG","TUR","LU1815336760.USD","BEZ","NUGT","LU0444973449.USD","LU1988902786.USD","LU2506951792.HKD","LITE","LU0476273544.USD","HIYY","RDW","BMNZ","FCVT","LU1642822529.SGD","BMNR","CRCL","BK4585","HIMZ","XLK","SMH","BK4588","RCAX"],"gpt_icon":1},{"id":"2618672446","title":"3月10日美股成交额前20：HIMS与诺和诺德达成合作，股价大涨逾40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618672446","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618672446?lang=zh_cn&edition=full","pubTime":"2026-03-10 04:48","pubTimestamp":1773089280,"startTime":"0","endTime":"0","summary":"周一美股成交额第1名英伟达收高2.72%，成交313.6亿美元。亿万富豪廖凯原周一再度增持英伟达，将其持股数量翻倍至200万股。　　摩尔维持对博通的“买入”评级，将其目标价从462美元上调至470美元，意味着约42%的上涨空间。　　此外，3月2日，英伟达宣布投资20亿美元并与Lumentum达成多年战略合作，包括数十亿美元采购高端激光元件的承诺，聚焦AI数据中心光学技术。　　该消息公布后，诺和诺德撤销了对该公司的诉讼，标志着双方争端的结束。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-10/doc-inhqmumf6558599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BKVL7J92.USD","BK4585","LU0154236417.USD","BK4599","BK4532","HIMS","NVO","HMYY","NVOH","BK4007","BK4196","LU1093756325.SGD","BK4588","NVOX","HIMY","HIMZ","IE00BZ1G4Q59.USD","HIYY","LU1093756168.USD"],"gpt_icon":1},{"id":"1162171962","title":"Hims与诺和诺德合作或引发短期逆风——市场快讯","url":"https://stock-news.laohu8.com/highlight/detail?id=1162171962","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162171962?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:53","pubTimestamp":1773060828,"startTime":"0","endTime":"0","summary":"早盘8点49分——Hims & Hers Health Inc.股价因诺和诺德终止对其诉讼并达成合作的消息而大幅飙升。根据协议，Hims平台将引入诺和诺德的GLP-1类药物。Truist分析师指出，尽管此举消除了Hims面临的重要法律风险，但合作可能对其短期业务造成冲击。\n作为协议的一部分，Hims将停止销售复合GLP-1药物，而这类药物曾贡献其大部分营收。不过，品牌GLP-1药物的收入持续性显著更高，尤其考虑到Hims的复合药物此前一直面临法律威胁。分析师认为，这一转变可能促使投资者愿意给予Hims更高估值倍数。受此影响，Hims股价在盘前交易中猛涨51%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","LU1093756325.SGD","IE00BKVL7J92.USD","HIYY","NVOH","HIMZ","BK4196","LU0154236417.USD","HIMS","BK4588","LU1093756168.USD","HIMY","BK4532","BK4585","BK4599","HMYY","NVOX","BK4007"],"gpt_icon":0},{"id":"1109539785","title":"FDA官员Makary表示欣慰：Hims将停止宣传未经批准的复方药物，转而通过与诺和诺德新合作销售FDA批准产品","url":"https://stock-news.laohu8.com/highlight/detail?id=1109539785","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109539785?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:50","pubTimestamp":1773060649,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）官员Makary近日发表声明，对Hims & Hers Health Inc.决定停止推广未经批准的复方药物表示赞赏。该公司将转向通过与新合作伙伴诺和诺德（Novo）建立的合作关系，专门销售获得FDA正式批准的医药产品。\n这一战略调整标志着Hims在合规经营和产品质量管控方面迈出重要一步。通过采用经FDA严格审批的标准化药物，既能保障患者用药安全，又有助于提升企业品牌信誉。与诺和诺德的合作预计将拓宽其合规产品的市场覆盖范围。\n行业观察人士指出，此举可能对在线医疗平台的产品监管合规性产生示范效应。随着监管环境日趋严格，更多企业或将重新评估其复方药物的营销策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMY","HIMS","HMYY","BK4196","HIMZ","HIYY"],"gpt_icon":0},{"id":"1127863922","title":"诺和诺德与Hims & Hers达成协议，后者将销售Wegovy和Ozempic并撤销诉讼，股价延续涨势","url":"https://stock-news.laohu8.com/highlight/detail?id=1127863922","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127863922?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:39","pubTimestamp":1773059964,"startTime":"0","endTime":"0","summary":"Hims & Hers Health Inc.  股价延续上涨态势，此前该公司与丹麦制药巨头诺和诺德达成合作协议，获得销售减肥药Wegovy和糖尿病药物Ozempic的授权。与此同时，诺和诺德已同意撤销对Hims & Hers提起的相关法律诉讼。分析人士指出，此次合作不仅解决了双方的法律纠纷，更为Hims & Hers打开了高达千亿美元的减肥药物市场大门。随着诺和诺德旗下明星产品Wegovy和Ozempic的加入，Hims & Hers的健康服务生态系统将得到进一步完善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIYY","HIMS","HIMZ","HIMY","BK4196","HMYY","NVO"],"gpt_icon":0},{"id":"2618356626","title":"诺和诺德确认将在HIMS & HERS平台上销售WEGOVY、OZEMPIC产品。","url":"https://stock-news.laohu8.com/highlight/detail?id=2618356626","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618356626?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:31","pubTimestamp":1773059515,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4532","BK4585","LU1093756168.USD","BK4599","HIMS","LU0154236417.USD","NVO","BK4007","IE00BKVL7J92.USD","NVOH","BK4196","NVOX","HIMZ","HMYY","HIYY","BK4588","HIMY"],"gpt_icon":0},{"id":"1146520715","title":"诺和诺德与Hims & Hers达成协议 美国消费者可自费获取Ozempic注射剂与Wegovy口服/注射制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1146520715","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146520715?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:31","pubTimestamp":1773059474,"startTime":"0","endTime":"0","summary":"根据最新合作协议，丹麦制药巨头诺和诺德与美国远程医疗平台Hims & Hers Health Inc.将共同为美国消费者开启新型减重疗法通道。消费者可通过自费方式获得诺和诺德旗下三款明星产品：Ozempic注射剂、Wegovy口服片剂及Wegovy注射剂。而Ozempic注射剂与Wegovy注射剂作为经过市场验证的成熟产品，将共同构成完整的体重管理解决方案。对于正在寻找替代传统分销渠道的诺和诺德而言，与Hims & Hers的合作或将开创代谢疾病管理的新范式。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HMYY","HIMY","HIYY","HIMS","NVO","HIMZ","BK4196"],"gpt_icon":1},{"id":"1123143091","title":"诺和诺德：撤回对Hims & Hers的专利侵权诉讼，但保留未来重新起诉权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1123143091","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123143091?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:31","pubTimestamp":1773059467,"startTime":"0","endTime":"0","summary":"诺和诺德(Novo Nordisk)已正式撤回对数字健康平台Hims & Hers Health Inc.提起的专利侵权诉讼。不过，这家丹麦制药巨头同时明确表示，其保留在未来针对相同事由再次提起诉讼的权利。\n此次诉讼的撤回标志着双方现阶段法律交锋的暂告段落，但诺和诺德此举也为其后续可能采取的法律行动预留了空间。市场分析认为，这反映了诺和诺德在保护其核心产品知识产权方面的持续决心与灵活策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","NVO","HIYY","HIMS","HMYY","HIMZ","HIMY"],"gpt_icon":0},{"id":"1174808259","title":"诺和诺德：Hims & Hers将停止在平台及营销中推广复合GLP-1产品","url":"https://stock-news.laohu8.com/highlight/detail?id=1174808259","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174808259?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:31","pubTimestamp":1773059466,"startTime":"0","endTime":"0","summary":"诺和诺德宣布，数字健康平台Hims & Hers Health Inc.已同意全面停止在其平台及营销材料中推广复合GLP-1受体激动剂产品。这一决定标志着诺和诺德在维护其GLP-1药物市场主导地位方面取得重要进展。\nHims & Hers此前通过线上渠道提供复合版本的GLP-1类药物，这类产品通常未经严格监管审批。此次调整将有助于规范相关疗法市场，确保患者获得经临床验证的正规药物。\n作为全球GLP-1疗法领导者，诺和诺德始终致力于通过法律和技术手段保护其知识产权。该协议也反映出医药行业对数字化医疗平台合规性日益严格的监管趋势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","NVO","HIMY","HIYY","HIMZ","HMYY","HIMS"],"gpt_icon":0},{"id":"1130360019","title":"Hims & Hers Health Inc.：计划在临床需要时提供复合GLP-1药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1130360019","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130360019?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:30","pubTimestamp":1773059442,"startTime":"0","endTime":"0","summary":"Hims & Hers Health Inc. 宣布，若医疗服务提供者认定复合药物在临床上是必要的，公司计划提供获取复合GLP-1药物的途径。此举旨在根据专业医疗判断，为有特定需求的患者提供更多治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","HIMZ","HMYY","HIYY","HIMS","HIMY"],"gpt_icon":0},{"id":"1157405095","title":"Hims & Hers Health盘后股价飙升39%，因报道称礼来与诺和诺德将合作销售减肥药","url":"https://stock-news.laohu8.com/highlight/detail?id=1157405095","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157405095?lang=zh_cn&edition=full","pubTime":"2026-03-07 08:58","pubTimestamp":1772845133,"startTime":"0","endTime":"0","summary":"受到一则关于制药巨头将联手销售减肥药物的报道提振，Hims & Hers Health Inc.的股价在盘后交易时段录得惊人涨幅，飙升幅度高达39%。\n市场消息称，礼来公司与诺和诺德计划在肥胖症治疗药物领域展开合作，共同进行市场推广与销售。这一重磅合作传闻立即在投资者中引发强烈反响，显示出市场对减肥药市场巨大潜力的高度认可。\n作为一家专注于提供远程医疗服务和个性化健康解决方案的公司，Hims & Hers Health Inc.被市场视为减肥药物需求增长的重要受益者。投资者预期，行业领军企业的强强联合将进一步扩大市场规模，从而为Hims & Hers等相关企业带来显著的业务增长机遇。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","HIYY","BK4196","HMYY","HIMS","HIMZ","HIMY"],"gpt_icon":0},{"id":"2617262656","title":"诺和诺德和HIMS将共同销售减肥药，结束双方的争端。","url":"https://stock-news.laohu8.com/highlight/detail?id=2617262656","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617262656?lang=zh_cn&edition=full","pubTime":"2026-03-07 08:34","pubTimestamp":1772843680,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4196","HIYY","NVO","BK4007","NVOH","BK4599","HIMZ","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4588","HIMY","HMYY","NVOX","LU0154236417.USD","BK4532","IE00BKVL7J92.USD","BK4585","HIMS","LU1093756325.SGD"],"gpt_icon":0},{"id":"1109675478","title":"摩根大通减持Hims & Hers Health股份，持股比例从8.1%降至1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109675478","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109675478?lang=zh_cn&edition=full","pubTime":"2026-03-06 00:55","pubTimestamp":1772729752,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的文件显示，截至2026年2月27日，摩根大通（JPMorgan Chase & Co.）已将其在远程医疗服务提供商Hims & Hers Health Inc.的持股比例大幅削减至1.7%。这一数据相较于2025年9月30日记录的8.1%持股比例，出现了显著下降。\n此次减持行动反映了摩根大通对Hims & Hers Health投资策略的重大调整。持股比例在不到五个月内下降超过6个百分点，凸显出机构投资者对该股票的看法可能正在发生变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0323591593.USD","LU2237443622.USD","LU1629891620.HKD","IE00B3S45H60.SGD","IE00BDRTCR15.USD","LU1116320901.HKD","IE00BLSP4239.USD","LU1720051017.SGD","LU0203345920.USD","BK4534","IE0034235295.USD","IE00BJLML261.HKD","LU0310799852.SGD","LU0208291251.USD","IE00B775SV38.USD","LU0149725797.USD","LU0106831901.USD","LU0689472784.USD","LU2552382132.HKD","LU0234572021.USD","IE00B1BXHZ80.USD","LU0265550359.USD","BK4207","LU2552382058.USD","BK4504","IE00BLSP4452.SGD","LU0943347566.SGD","LU0683600562.USD","LU2381873111.SGD","LU1974910355.USD","LU2023250843.SGD","LU1032466523.USD","LU1084165304.USD","LU2430703178.SGD","LU2756315664.SGD","IE00BHPRN162.USD","LU1116320737.USD","IE0034235188.USD","LU2237443978.SGD","IE00BDCRKT87.USD","IE00BBT3K403.USD","LU0170899867.USD","LU1670628061.USD","BK4585","LU2264538146.SGD","BK4566","LU0971096721.USD","LU2592432038.USD","LU2237443382.USD","LU0820561909.HKD","LU0006306889.USD","LU0267386448.USD","BK4516","JPMO","LU0345769128.USD","LU1917777945.USD","LU1551013425.SGD","LU1363072403.SGD","LU1261432733.SGD","LU2237443465.HKD","LU2746668461.USD","LU2756315318.SGD","LU0882574139.USD","LU1267930490.SGD","LU2023250330.USD","LU1244550494.USD","LU0320765489.SGD","LU0211331839.USD","LU2213496289.HKD","LU2106854487.HKD","LU1894683348.USD","LU0496365809.HKD","SG9999002224.SGD","BK4550","LU0211328371.USD","LU0320765646.SGD","HIMS","IE00B1XK9C88.USD","LU0640476718.USD","LU2505996681.GBP","SG9999002232.USD","LU0211327993.USD","LU0238689110.USD","LU0265550946.USD","LU2552382215.SGD","IE00BZ1G4Q59.USD","LU2242649171.HKD","LU0345770308.USD","LU1162221912.USD","LU0345769631.USD","LU2505996509.AUD","LU0964807845.USD","LU1670627923.USD","LU1244550577.SGD","LU2236285917.USD","LU0868494617.USD","LU0215105999.USD","LU2054465674.USD","BK4533","LU0211326839.USD","IE0034235303.USD","LU0048584097.USD","IE00BKDWB100.SGD","LU2456880835.USD","BK4588","IE00BKVL7J92.USD","IE000M9KFDE8.USD","HIMY","IE00BFXG1179.USD","IE00BWXC8680.SGD","LU2237443549.SGD","LU2211815571.USD","IE00BYXW3230.USD","LU2023250504.SGD","LU1548497426.USD","LU2357305700.SGD","HMYY","LU1064131342.USD","BK4581","LU0211326755.USD","LU1145028129.USD","LU1496350171.SGD","LU0820562030.AUD","LU2237443895.HKD","LU0942090050.USD","LU1119994496.HKD","LU0976567544.SGD","LU2430703095.HKD","LU0820561818.USD","LU2462157665.USD","LU0417517546.SGD","JPM","LU1914381329.SGD","LU0787776722.HKD","BK4196","LU0868494708.USD","LU0070302665.USD","LU1496350502.SGD","IE00BN8TJ469.HKD","LU1720051108.HKD","LU0203347892.USD","LU1280957306.USD","LU1894683264.USD","LU2430703251.USD","LU2746668974.SGD","LU0251132253.USD","LU1366192091.USD","HIMZ","LU1244550221.USD","IE00BJTD4N35.SGD","LU1988902786.USD","LU0345770993.USD","LU0106261372.USD","LU1551013342.USD","IE00BJTD4V19.USD","LU0256863811.USD","HIYY","LU1668664300.SGD","LU2417539215.USD"],"gpt_icon":0},{"id":"2613103007","title":"美股异动 | Q4营收低于预期 Hims & Hers Health(HIMS.US)盘前跌超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613103007","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613103007?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:23","pubTimestamp":1771942999,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周二，Hims & Hers Health盘前跌超7%，报14.40美元。消息面上，该公司2025年第四季度营收6.1782亿美元，同比增长28%，但低于预期的6.1922亿;每股收益0.08美元，超出预期的0.03。订阅用户数超过250万人，毛利率从一年前的77%收窄至72%。该公司预计第一季度营收介于6亿至6.25亿之间，低于预期的6.5312亿，并预计2026财年全年收入介于27亿至29亿之间，而市场预期为27.4亿。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"0fffc80212931f337b90385d4073028f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406876.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["TNA","BK4581","BK4534","BK4588","IWO","BK4550","HMYY","BK4196","RWM","HIMZ","TZA","BK4535","HIMY","SRTY","HIYY","MNQmain","IWN","UWM","TWM","HIMS","BK4585"],"gpt_icon":0},{"id":"2613560764","title":"Hims & Hers Health第四季度销售额增长，但对第一季度业绩预期偏低","url":"https://stock-news.laohu8.com/highlight/detail?id=2613560764","media":"新浪财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613560764?lang=zh_cn&edition=full","pubTime":"2026-02-24 13:54","pubTimestamp":1771912452,"startTime":"0","endTime":"0","summary":"这份财报发布之际，Hims & Hers正面临诺和诺德提起的诉讼，后者要求禁止该公司销售其减重药物的仿制品。诺和诺德指控Hims & Hers侵犯司美格鲁肽相关专利，而Hims & Hers则批评该诉讼是在打压平价药物选择。Hims & Hers的减重业务是其发展关键。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224135638a7188754&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224135638a7188754&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HIMS","HIMZ","BK4196","HIYY","HIMY","HMYY"],"gpt_icon":1},{"id":"1131573891","title":"Hims & Hers Health：SEC文件称，目前尚不清楚FDA、HHS或司法部将对复合GLP-1产品的营销采取何种行动","url":"https://stock-news.laohu8.com/highlight/detail?id=1131573891","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131573891?lang=zh_cn&edition=full","pubTime":"2026-02-24 06:34","pubTimestamp":1771886088,"startTime":"0","endTime":"0","summary":"根据Hims & Hers Health Inc.提交给美国证券交易委员会（SEC）的文件，目前尚不清楚美国食品和药物监督管理局（FDA）、美国卫生与公众服务部（HHS）或司法部（DOJ）可能对复合GLP-1产品的营销采取何种监管行动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","HIYY","HMYY","HIMZ","HIMS","HIMY"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.2599},{"period":"1month","weight":-0.0882},{"period":"3month","weight":-0.4724},{"period":"6month","weight":-0.6773},{"period":"ytd","weight":-0.3659}],"compareEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":-0.0179},{"period":"3month","weight":-0.007},{"period":"6month","weight":0.04},{"period":"1year","weight":0.1777},{"period":"ytd","weight":-0.0054}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"exchange":"ARCA","name":"YieldMax HIMS Option Income Strategy ETF","nameEN":"YieldMax HIMS Option Income Strategy ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"YieldMax HIMS Option Income Strategy ETF(HIYY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供YieldMax HIMS Option Income Strategy ETF(HIYY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"YieldMax HIMS Option Income Strategy ETF,HIYY,YieldMax HIMS Option Income Strategy ETF股票,YieldMax HIMS Option Income Strategy ETF股票老虎,YieldMax HIMS Option Income Strategy ETF股票老虎国际,YieldMax HIMS Option Income Strategy ETF行情,YieldMax HIMS Option Income Strategy ETF股票行情,YieldMax HIMS Option Income Strategy ETF股价,YieldMax HIMS Option Income Strategy ETF股市,YieldMax HIMS Option Income Strategy ETF股票价格,YieldMax HIMS Option Income Strategy ETF股票交易,YieldMax HIMS Option Income Strategy ETF股票购买,YieldMax HIMS Option Income Strategy ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"YieldMax HIMS Option Income Strategy ETF(HIYY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供YieldMax HIMS Option Income Strategy ETF(HIYY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}